CNAT Conatus Pharmaceuticals Inc.

0.41
-0.01  -2%
Previous Close 0.42
Open 0.43
Price To Book 0.62
Market Cap 13,672,875
Shares 33,170,487
Volume 714,275
Short Ratio
Av. Daily Volume 654,295
Stock charts supplied by TradingView

NewsSee all news

  1. Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board Member

    SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an additional independent member. "We

  2. Conatus Pharmaceuticals Reports Third Quarter 2019 Financial Results

    SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced financial results for the quarter and nine months ended September 30, 2019. Recent Developments In June 2019,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data June 24, 2019 did not meet primary endpoint.
Emricasan
NASH cirrhosis - ENCORE-LF trial
Phase 2b data released December 5, 2018 did not meet primary endpoint.
Emricasan
NASH cirrhosis - ENCORE-PH trial
Phase 2 topline data released Jan 2015
Emricasan
Acute-on-Chronic Liver Failure (ACLF)
Phase 2b data released April 4, 2018. Primary endpoint not met.
Emricasan
Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)
Phase 2b trial did not meet primary endpoint - March 21, 2019.
Emricasan
NASH fibrosis - ENCORE-NF trial
Phase 2 topline data released early January 2016
Emricasan
Liver Cirrhosis
Phase 2 data released September 2015.
Emricasan
Portal Hypertension

Latest News

  1. Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board Member

    SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an additional independent member. "We

  2. Conatus Pharmaceuticals Reports Third Quarter 2019 Financial Results

    SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced financial results for the quarter and nine months ended September 30, 2019. Recent Developments In June 2019,